AzTrials
AzTrials

Duchenne Muscular Dystrophy (DMD)GUP23005NCT07890883

Bone Health in Adults With Duchenne Muscular Dystrophy: A Survey on Osteoporosis, Fractures and Treatment.

An observational study of Duchenne Muscular Dystrophy (DMD), run by Istituto Giannina Gaslini at 15 sites in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

Background and Rationale Duchenne muscular dystrophy (DMD) is a genetic disorder caused by mutations in the dystrophin gene, resulting in progressive muscle weakness and multiple complications, including respiratory and cardiac impairment, osteoporosis (OP), and fragility fractures (FF). Read more about this study

Who is it for?
Ages 18 to 44 years, men onlyHealthy volunteers can take part
Conditions the study is for
Duchenne Muscular Dystrophy (DMD)
How many people
200 participants
Where
15 sitesItaly
Study dates
11 Apr 2024to 31 Dec 2026
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 44 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Study population: The study population will include approximately 200 adult patients with Duchenne muscular dystrophy (DMD), aged over 18 years, recruited from 15 Italian tertiary referral centers specializing in neuromuscular diseases. A control group of 50 healthy male subjects aged over 18 years will be recruited exclusively at IRCCS Istituto Giannina Gaslini for serum biomarker analysis.

Who may be able to join

  • Genetic or histological diagnosis of Duchenne muscular dystrophy (DMD).
  • Age over 18 years.
  • Willingness to participate in the study and provision of written informed consent.

Who cannot join

  • Current enrollment in another clinical study.
  • Inability to undergo dual-energy X-ray absorptiometry (DXA) due to severe kyphoscoliosis.
  • Previous surgery for scoliosis.
  • Severe respiratory failure, defined as the need for non-invasive ventilation (NIV) 24 hours per day or the presence of a tracheostomy.
  • Severe cardiomyopathy, defined as a left ventricular ejection fraction (LVEF) below 30%.
  • Severe intellectual disability (IQ below 45) and inability to perform functional assessments.

Trial locations and contacts

15 sites in 1 country. Contact the study team or a site near you to ask about taking part.

15 sites in 1 country

Italy15 sites, 15 recruiting
  • Centro Malattie Neuromuscolari dell'età Evolutiva, Bologna

    Bologna

    Melania Giannotta, +39 051 4966159, npi.malattieneuromuscolari@ausl.bologna.it

    Recruiting
  • Associazione La Nostra Famiglia Eugenio Medea IRCCS, Bosisio Parini

    Bosisio Parini

    Eleonora Diella, +39 031 877829, polo.bosisio@lanostrafamiglia.it

    Recruiting
  • Associazione La Nostra Famiglia Eugenio Medea IRCCS, Conegliano

    Conegliano, 31015

    Massimo Cordini, +39 0438 4141, irccs@cn.lnf.it

    Recruiting
  • IRCCS Istituto Giannina Gaslini

    Genova, 16147

    Chiara Panicucci, +39 010 56362756, chiarapanicucci@gaslini.org

    Recruiting
  • Dipartimento di Scienze Cliniche e Sperimentali, Università di Brescia

    Gussago

    Massimiliano Filosto Massimiliano Filosto, +39 030 6729100, dscs@cert.unibs.it

    Recruiting
  • Azienda Universitaria Policlinico G. Martino

    Messina

    Sonia Messina, +39 090 221 7178, urp@polime.it

    Recruiting
  • Fondazione IRCCS Istituto. Neurologico "C. Besta", Milano

    Milan

    Lorenzo Maggi, +39 02 2394 2282, neurologia4@istituto-besta.it

    Recruiting
  • Università degli Studi di Milano Statale

    Milan

    Emilio Albamonte, +39 02 9143 371, info@centrocliniconemo.it

    Recruiting
  • Università degli Studi della Campania Luigi Vanvitelli, Napoli

    Naples

    Vincenzo Nigro, +39 081 566 5704, dip.medicinadiprecisione@unicampania.it

    Recruiting
  • Dipartimento di Neuroscienze Università di Padova

    Padova

    Luca Bello, +39 049 827 2025, dip.neuroscienze@unipd.it

    Recruiting
  • Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa

    Pisa

    Gabriele Siciliano, +39 050 993212, amb.neuromuscpisa@ao-pisa.toscana.it

    Recruiting
  • Fondazione Stella Maris IRCCS-Pisa

    Pisa

    Roberta Battini, +39 050 886282, lmalucelli@fsm.unipi.it

    Recruiting
  • Dipartimento di Neuroscienze IRCCS Ospedale Bambino Gesù, Roma

    Roma

    Michela Catteruccia, +39 06 6859 2105, neurologia@opbg.net

    Recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli, Roma

    Roma

    Concetta Palermo, +39 06 3015 6391, pediatrico.roma@centrocliniconemo.it

    Recruiting
  • Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, Siena

    Siena

    Diego Lopergolo, +39 0577 585760, neurometaboliche@ao-siena.toscana.it

    Recruiting

Other trials in Italy

About this study

Official title: Bone Health in Adult Patients With Duchenne Muscular Dystrophy: A Survey on Osteoporosis, Fractures, and Their Treatment.

Background and Rationale Duchenne muscular dystrophy (DMD) is a genetic disorder caused by mutations in the dystrophin gene, resulting in progressive muscle weakness and multiple complications, including respiratory and cardiac impairment, osteoporosis (OP), and fragility fractures (FF). Bone fragility is a major concern, as lower-limb fractures may accelerate the loss of independent ambulation and complicate daily care. Despite increased life expectancy, bone health in adults with DMD remains insufficiently investigated. This study aims to address this knowledge gap and improve the understanding and management of skeletal complications in this population.

Objectives

Read more

The study aims to: (1) determine the prevalence of fragility fractures in adults with DMD; (2) identify childhood and adolescent risk or protective factors affecting adult bone health; (3) collect data on fracture treatment; (4) measure serum analytes involved in bone metabolism and bone-muscle crosstalk; and (5) identify genetic modifiers associated with increased fracture risk.

Study Population

Approximately 200 patients with DMD aged over 18 years will be recruited from 15 Italian tertiary referral centers specializing in neuromuscular diseases. A control group of healthy males aged over 18 years will be recruited exclusively at the coordinating center. Controls will undergo only a blood collection of approximately 3 mL for serum analysis.

Study Design and Procedures Patients will undergo respiratory assessment, including peak expiratory flow (PEF), forced vital capacity (FVC), and respiratory support requirements; orthopedic assessment of scoliosis, contractures, deformities, and previous spinal fusion surgery; motor function assessment using the North Star Ambulatory Assessment (NSAA); upper-limb function assessment using the Performance of the Upper Limb (PUL) scale; and the Six-Minute Walk Test (6MWT). Imaging procedures will include a lateral thoracolumbar spine radiograph (T4-L4) and dual-energy X-ray absorptiometry (DXA) of the lumbar spine (L1-L4) and total body less head (TBLH). Clinical and medical history data will be recorded using a dedicated case report form (CRF).

Biological Samples and Analyses One blood sample of approximately 3 mL will be collected for serum extraction and analysis of metabolites involved in bone metabolism and bone-muscle crosstalk. Samples will be centralized at the coordinating center and then sent to the University of Campania "Luigi Vanvitelli" for analysis. Healthy control samples will be used for comparison.

Two additional blood tubes, totaling approximately 6 mL, will be collected for DNA extraction and genome-wide association studies (GWAS), aimed at identifying genetic modifiers associated with increased fracture risk. These samples will be centralized and subsequently sent to the University of Padua for genetic analysis.

Data Management and Ethics Study data will be anonymized and managed in accordance with the General Data Protection Regulation (GDPR, EU 2016/679) and the Declaration of Helsinki. Patients and/or their legally authorized representatives will receive the study information and provide written informed consent before participation. Investigators will declare any potential conflicts of interest.

Expected Outcomes The study will characterize bone health and fragility fracture prevalence in adults with DMD, describe fracture management, and investigate clinical, developmental, biochemical, and genetic factors associated with fracture risk. The findings may help improve fracture prevention, bone health monitoring, and clinical management in this population.

Medical subject headings
Muscular Dystrophy, Duchenne

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07890883
Study groupRoleWhat they receive
DMD patients (study group)Approximately 200 adult patients with Duchenne muscular dystrophy (DMD), aged over 18 years, recruited from 15 Italian centers.
Healthy controls (control group)Healthy male subjects aged over 18 years, recruited exclusively at IRCCS Istituto Giannina Gaslini, who will undergo only a blood sample collection of approximately 3 mL.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prevalence of Fragility Fractures in Adult Patients with DMD

    To determine the prevalence of extremity fractures in adult patients with Duchenne muscular dystrophy based on review of clinical records.

    Measured: Baseline

Secondary outcomes (16)
  1. Prevalence of Vertebral Fractures in Adult Patients with DMD

    To determine the prevalence of vertebral fractures in adult patients with Duchenne muscular dystrophy based on lateral thoracolumbar spine radiographs (T4-L4).

    Measured: Baseline

  2. Fracture Treatment Patterns

    To describe the treatments administered for fragility fractures in adult patients with Duchenne muscular dystrophy.

    Measured: Baseline

  3. Serum Biomarkers of Bone Metabolism and Bone-Muscle Crosstalk

    To measure serum analytes involved in bone metabolism and bone-muscle crosstalk in patients with DMD and compare their levels with those of healthy male controls.

    Measured: Baseline

  4. Genetic Modifiers Associated with Fracture Risk

    To identify genetic variants potentially associated with an increased risk of fractures in patients with DMD through DNA analysis and genome-wide association studies (GWAS).

    Measured: Baseline

  5. Bone Mineral Density of the Lumbar Spine (L1-L4)

    To assess bone mineral density at the lumbar spine (L1-L4) using dual-energy X-ray absorptiometry (DXA).

    Measured: Baseline

  6. Bone Mineral Density of Total Body Less Head (TBLH)

    To assess bone mineral density of total body less head (TBLH) using dual-energy X-ray absorptiometry (DXA).

    Measured: Baseline

  7. Peak Expiratory Flow (PEF)

    To assess respiratory function by measuring peak expiratory flow (PEF).

    Measured: Baseline

  8. Forced Vital Capacity (FVC)

    To assess respiratory function by measuring forced vital capacity (FVC).

    Measured: Baseline

  9. Respiratory Support Status

    To record respiratory support status at the study visit.

    Measured: Baseline

  10. Presence of Scoliosis

    To record the presence of scoliosis based on the orthopedic assessment.

    Measured: Baseline

  11. Presence of Contractures

    To record the presence of contractures based on the orthopedic assessment.

    Measured: Baseline

  12. Other Orthopedic Deformities

    To characterize other orthopedic deformities identified during the orthopedic assessment.

    Measured: Baseline

  13. History of Arthrodesis

    To record whether the patient has undergone an arthrodesis procedure, based on the clinical history and orthopedic assessment.

    Measured: Baseline

  14. Motor Function Assessed by NSAA

    To assess motor function using the North Star Ambulatory Assessment (NSAA).

    Measured: Baseline

  15. Upper-Limb Function Assessed by PUL

    To assess upper-limb motor function using the Performance of Upper Limb (PUL) scale.

    Measured: Baseline

  16. Walking Capacity Assessed by 6MWT

    To assess walking capacity using the Six-Minute Walk Test (6MWT).

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Oct 2026
  2. Study start11 Apr 2024
  3. Primary completion28 Feb 2026
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07890883
Sponsor's protocol ID
GUP23005 (13634)
Acronym
GUP23005
Status last verified
Oct 2026
First submitted
9 Oct 2026
Last updated
22 Oct 2026
Results posted
No
Individual data sharing
Undecided

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in